Biotricity Q2 FY2023 revenue $2.4M, up 14% sequentially; net loss $4.9M

BIOTRICITY INC.

2024-Q2 EPS reported -$1.15 revenue$4,437,441

Revenue $2.4M, up 14% QoQ; gross profit $1.3M (54% margin).
Net loss $4.9M ($0.094 per share) for quarter ended Sept 30, 2022.
Bioheart monitor won TIME's Best Inventions 2022; awarded $250K NIH grant.
Surpassed 2 billion recorded heartbeats for AFib; launched Biocare Cardiac Disease Management Solution.
Maintained 95%+ customer retention; new distribution partnerships signed.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

BIOTRICITY INC. reported fiscal 2023 second quarter ended September 30, 2022 results: revenue $2.4 million, net income $4.9 million, EPS $0.094 per share.

Period: fiscal 2023 second quarter ended September 30, 2022
Revenue: $2.4 million
Net income: $4.9 million
EPS: $0.094 per share
Result: reported results

Exact text from the filing

Q2-FY23 Financial Highlights: ● Revenue totaled $2.4 million. ● Gross profit totaled $1.3 million. ● Gross profit margins were 54%. ● Net loss totaled $4.9 million or $0.094 per share.

View on SEC.gov

Browse all earnings releases →

BIOTRICITY INC. filing history →

Source: SEC EDGAR

accession 0001493152-22-032857

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.